NCT06798896View on ClinicalTrials.gov

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures

PHASE2RecruitingINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Focal Onset Seizures
Interventions
DRUG

SPN-817

SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

DRUG

Placebo

Placebo, bid

Trial Locations (1)

33952

RECRUITING

Medsol Clinical Research Center, Port Charlotte

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY